Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces
Post# of 421
(Total Views: 271)
Posted On: 11/18/2021 3:26:59 PM
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces 2022 DehydraTECH(TM) R&D Programs, Including Investigations into Alzheimer’s Disease and Diabetes
- Lexaria’s 2022 R&D programs are set to include research on hormone replacement, dementia, rheumatoid disease, and diabetes, among other conditions
- The program builds on findings from 2021 studies which supported significant advances in the oral nicotine, heart disease, and antiviral markets
- The 2022 program will continue to focus on the company’s patented DehydraTECH drug delivery platform
- Lexaria will also be conducting pharmacokinetic and efficacy modeling studies in animals to evaluate DehydraTECH’s overall efficiency
In 2021, Lexaria Bioscience (NASDAQ: LEXX) raised approximately $15 million in funding. The money allowed for active work programs throughout the year while supporting significant advances in oral nicotine, heart disease, and antiviral research. Lexaria plans to take the findings from these 2021 studies and improve them with the 2022 R&D programs, which include hormone replacement, dementia, diabetes, and rheumatoid disease (https://nnw.fm/Z0bMo).
While making the announcement, Chris Bunka, the Chief Executive Officer (“CEO”) of Lexaria, noted, “Calendar 2022 will continue to see significant milestones in utilizing DehydraTECH-CBD for investigation of heart disease and hypertension, and separately, for oral nicotine delivery as an alternative to smoking.”
“We are delighted to announce that DehydraTECH as an enhanced drug delivery platform will also be evaluated for characteristics and potential treatment options for hormone replacement, dementia, rheumatoid disease, and diabetes,” he added.
Lexaria announced a fraction of their 2022 applied R&D programs, among them HOR-A22-1, DEM-A22-1, RHEUM-A22-1, and DIAB-A22-1.
HOR-A22-1, slated for April 2022, will be a hormone replacement study. It will evaluate the ability of Lexaria’s patented DehydraTECH to enhance estrogen among patients, allowing for the control of the menstrual cycle, cholesterol, and the protection of bone health. Through this study, Lexaria plans to capitalize on the hormone replacement market, which is estimated to grow to $46.5 billion by 2027.
DEM-A22-1, scheduled for July 2022, will explore the efficiency of DehydraTECH-CBD, with and without nicotine, for the potential treatment of dementia. Once again, Lexaria plans to capitalize on the dementia drug market, which is estimated to grow to $19.6 billion by 2026.
RHEUM-A22-1, scheduled for October 2022, will focus on rheumatoid disease treatment through the use of DehydraTECH-CBD. Through this study, Lexaria intends to take advantage of the growing Rheumatoid Arthritis Therapeutics market, which is projected to be valued at $30 billion by 2025.
DIAB-A22-1, which is slated for November 2022, will evaluate the ability of DehydraTECH-CBD to potentially affect the treatment of diabetes. Studies so far have shown that CBD can reduce the incidence of diabetes in mice, a significant milestone in the study. Improving on these findings, Lexaria is strategically evaluating the prescription drug market used to treat diabetes, an industry expected to be valued at $77.9 billion by 2024.
In addition to these studies, Lexaria also announced that it would be conducting pharmacokinetic (“PK”) and efficacy modeling studies in animals to evaluate DehydraTECH’s ability to improve the delivery characteristics of various other drugs or active pharmaceutical ingredients (“APIs”). The goal would be to identify whether there could be a commercial benefit to continue further studies and pursuit within different market sectors.
Lexaria has been vocal about its R&D initiatives and endeavors. Additionally, it has remained true to its objective to build significant value for all its stakeholders while also pursuing policies for substantial improvements to human health. The 2022 work programs are the company’s next biggest undertakings, and they stay true to what it stands for, along with its commitment to its stakeholders.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Lexaria’s 2022 R&D programs are set to include research on hormone replacement, dementia, rheumatoid disease, and diabetes, among other conditions
- The program builds on findings from 2021 studies which supported significant advances in the oral nicotine, heart disease, and antiviral markets
- The 2022 program will continue to focus on the company’s patented DehydraTECH drug delivery platform
- Lexaria will also be conducting pharmacokinetic and efficacy modeling studies in animals to evaluate DehydraTECH’s overall efficiency
In 2021, Lexaria Bioscience (NASDAQ: LEXX) raised approximately $15 million in funding. The money allowed for active work programs throughout the year while supporting significant advances in oral nicotine, heart disease, and antiviral research. Lexaria plans to take the findings from these 2021 studies and improve them with the 2022 R&D programs, which include hormone replacement, dementia, diabetes, and rheumatoid disease (https://nnw.fm/Z0bMo).
While making the announcement, Chris Bunka, the Chief Executive Officer (“CEO”) of Lexaria, noted, “Calendar 2022 will continue to see significant milestones in utilizing DehydraTECH-CBD for investigation of heart disease and hypertension, and separately, for oral nicotine delivery as an alternative to smoking.”
“We are delighted to announce that DehydraTECH as an enhanced drug delivery platform will also be evaluated for characteristics and potential treatment options for hormone replacement, dementia, rheumatoid disease, and diabetes,” he added.
Lexaria announced a fraction of their 2022 applied R&D programs, among them HOR-A22-1, DEM-A22-1, RHEUM-A22-1, and DIAB-A22-1.
HOR-A22-1, slated for April 2022, will be a hormone replacement study. It will evaluate the ability of Lexaria’s patented DehydraTECH to enhance estrogen among patients, allowing for the control of the menstrual cycle, cholesterol, and the protection of bone health. Through this study, Lexaria plans to capitalize on the hormone replacement market, which is estimated to grow to $46.5 billion by 2027.
DEM-A22-1, scheduled for July 2022, will explore the efficiency of DehydraTECH-CBD, with and without nicotine, for the potential treatment of dementia. Once again, Lexaria plans to capitalize on the dementia drug market, which is estimated to grow to $19.6 billion by 2026.
RHEUM-A22-1, scheduled for October 2022, will focus on rheumatoid disease treatment through the use of DehydraTECH-CBD. Through this study, Lexaria intends to take advantage of the growing Rheumatoid Arthritis Therapeutics market, which is projected to be valued at $30 billion by 2025.
DIAB-A22-1, which is slated for November 2022, will evaluate the ability of DehydraTECH-CBD to potentially affect the treatment of diabetes. Studies so far have shown that CBD can reduce the incidence of diabetes in mice, a significant milestone in the study. Improving on these findings, Lexaria is strategically evaluating the prescription drug market used to treat diabetes, an industry expected to be valued at $77.9 billion by 2024.
In addition to these studies, Lexaria also announced that it would be conducting pharmacokinetic (“PK”) and efficacy modeling studies in animals to evaluate DehydraTECH’s ability to improve the delivery characteristics of various other drugs or active pharmaceutical ingredients (“APIs”). The goal would be to identify whether there could be a commercial benefit to continue further studies and pursuit within different market sectors.
Lexaria has been vocal about its R&D initiatives and endeavors. Additionally, it has remained true to its objective to build significant value for all its stakeholders while also pursuing policies for substantial improvements to human health. The 2022 work programs are the company’s next biggest undertakings, and they stay true to what it stands for, along with its commitment to its stakeholders.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)